Skip to content
OpenCapital
Get started

ANI Pharmaceuticals ANIP Unapproved Products — Net Revenues

Similar metrics at other companies

Aurinia Pharmaceuticals logo
AUPHNet product sales — Revenue
$73.56M+22.7%
Bristol-Myers Squibb logo
BMYNet product sales — Total Revenues
$11.17B+2.6%
Amneal Pharmaceuticals, Inc. logo
AMRXOther dosage forms — Net revenue
$46.61M-17.4%
Exelixis logo
EXELNet product revenues — Total revenues
$554.98M+8.1%
BioMarin Pharmaceuticals logo
BMRNNet product revenues — Total revenues
$760.08M+3.5%
Vertex Pharmaceuticals logo
VRTXProduct revenues, net — Product revenues, net
$2.99B+8.2%

Other financials

Income statement

See full
Revenue$237.5M+20.5%
Gross profit$143.9M+16.0%
Operating income$38.9M+48.5%
Net income$29.5M+88.1%
EPS (diluted)$1.28+85.5%

Balance sheet

See full
Cash & equivalents$311.2M+108%
Total debt$305.3M-3.5%
Total equity$562.3M+34.3%
Total assets$1.4B+10.0%

Cash flow

See full
Operating cash flow$58.4M+66.8%
CapEx$6.1M+146%
Free cash flow$52.3M+60.8%

Valuation

See full
Market cap$1.88B+18.3%
Enterprise value$1.87B+5.8%
P/E20.4×—
P/S2×-0.3×

Profitability

See full
Gross margin60.8%+1.5pp
Operating margin13.4%—
Net margin10%+8.1pp
FCF margin20.7%+10.8pp

Returns & leverage

See full
Return on equity18.8%+15.6pp
Debt / equity0.5×-0.2×
Current ratio3.1×+0.5×

Where this comes from

Reported directly by ANI Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: ANI Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about ANI Pharmaceuticals's unapproved products — net revenues.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ANI Pharmaceuticals's unapproved products — net revenues?
ANI Pharmaceuticals (ANIP) reported unapproved products — net revenues of $6.3M in Q1 2026.
How has ANI Pharmaceuticals's unapproved products — net revenues changed year-over-year?
ANI Pharmaceuticals's unapproved products — net revenues increased by 14.5% year-over-year, from $5.5M to $6.3M.
What is the long-term trend for ANI Pharmaceuticals's unapproved products — net revenues?
Over 4 years (2021 to 2025), ANI Pharmaceuticals's unapproved products — net revenues has grown at a 10.4% compound annual growth rate (CAGR), from $16.2M to $24.1M.
What does unapproved products — net revenues mean?
This metric represents the total net revenue generated from the sale of pharmaceutical products that have not yet received formal regulatory approval but are permitted for sale under specific grandfathering or compliance frameworks. It serves as a measure of the company's ability to monetize legacy or niche product portfolios that operate outside the standard new drug approval pathway. Monitoring this revenue stream provides insight into the stability and contribution of non-core, legacy assets to the overall top-line performance.